Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®
Bosaya™ and Vevzuo™ (both denosumab products) now approved by Health Canada Potential benefit to more than 2 million adults with osteoporosis and hundreds of patients annually with bone metastasis, a common complication of advanced cancer TORONTO & BENGALURU, India — Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, is pleased to announce […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.